ZFIN ID: ZDB-FIG-170908-40
Mathews et al., 2016 - Cholesterol Biosynthesis Supports Myelin Gene Expression and Axon Ensheathment through Modulation of P13K/Akt/mTor Signaling. The Journal of neuroscience : the official journal of the Society for Neuroscience   36:7628-39 Full text @ J. Neurosci.
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Fish:
Conditions:
Knockdown Reagents:
Anatomical Term:
Stage: Day 4
PHENOTYPE:
Fish:
Conditions:
Knockdown Reagents:
Observed In:
Stage: Day 4

Fig. 4 ZFIN is incorporating published figure images and captions as part of an ongoing project. Figures from some publications have not yet been curated, or are not available for display because of copyright restrictions.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
mbpa WT + MO1-ptena + MO4-tp53 control Day 4 hindbrain oligodendrocyte ISH
WT + MO1-ptena + MO4-tp53 chemical treatment by environment: sirolimus Day 4 hindbrain oligodendrocyte ISH
WT + MO1-ptena + MO4-tp53 chemical treatment by environment: U0126 Day 4 hindbrain oligodendrocyte ISH
WT + MO4-tp53 control Day 4 hindbrain oligodendrocyte ISH
WT + MO4-tp53 chemical treatment by environment: sirolimus Day 4 hindbrain oligodendrocyte ISH
WT + MO4-tp53 chemical treatment by environment: U0126 Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO1-ptena + MO4-tp53 control Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO1-ptena + MO4-tp53 chemical treatment by environment: sirolimus Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO1-ptena + MO4-tp53 chemical treatment by environment: U0126 Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO4-tp53 control Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO4-tp53 chemical treatment by environment: sirolimus Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO4-tp53 chemical treatment by environment: U0126 Day 4 hindbrain oligodendrocyte ISH
plp1a WT + MO1-ptena + MO4-tp53 control Day 4 hindbrain oligodendrocyte ISH
WT + MO1-ptena + MO4-tp53 chemical treatment by environment: sirolimus Day 4 hindbrain oligodendrocyte ISH
WT + MO1-ptena + MO4-tp53 chemical treatment by environment: U0126 Day 4 hindbrain oligodendrocyte ISH
WT + MO4-tp53 control Day 4 hindbrain oligodendrocyte ISH
WT + MO4-tp53 chemical treatment by environment: sirolimus Day 4 hindbrain oligodendrocyte ISH
WT + MO4-tp53 chemical treatment by environment: U0126 Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO1-ptena + MO4-tp53 control Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO1-ptena + MO4-tp53 chemical treatment by environment: sirolimus Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO1-ptena + MO4-tp53 chemical treatment by environment: U0126 Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO4-tp53 control Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO4-tp53 chemical treatment by environment: sirolimus Day 4 hindbrain oligodendrocyte ISH
hmgcs1vu57/vu57 + MO4-tp53 chemical treatment by environment: U0126 Day 4 hindbrain oligodendrocyte ISH
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
hmgcs1vu57/vu57 + MO1-ptena + MO4-tp53 control Day 4 hindbrain oligodendrocyte mbpa expression amount, ameliorated
Day 4 hindbrain oligodendrocyte plp1a expression amount, ameliorated
Day 4 hindbrain oligodendrocyte development process quality, ameliorated
hmgcs1vu57/vu57 + MO1-ptena + MO4-tp53 chemical treatment by environment: sirolimus Day 4 hindbrain oligodendrocyte mbpa expression decreased amount, abnormal
Day 4 hindbrain oligodendrocyte plp1a expression decreased amount, abnormal
Day 4 hindbrain oligodendrocyte development decreased process quality, abnormal
hmgcs1vu57/vu57 + MO1-ptena + MO4-tp53 chemical treatment by environment: U0126 Day 4 hindbrain oligodendrocyte mbpa expression amount, ameliorated
Day 4 hindbrain oligodendrocyte plp1a expression amount, ameliorated
Day 4 hindbrain oligodendrocyte development process quality, ameliorated
hmgcs1vu57/vu57 + MO4-tp53 control Day 4 hindbrain oligodendrocyte mbpa expression decreased amount, abnormal
Day 4 hindbrain oligodendrocyte plp1a expression decreased amount, abnormal
Day 4 hindbrain oligodendrocyte development decreased process quality, abnormal
hmgcs1vu57/vu57 + MO4-tp53 chemical treatment by environment: sirolimus Day 4 hindbrain oligodendrocyte mbpa expression decreased amount, abnormal
Day 4 hindbrain oligodendrocyte plp1a expression decreased amount, abnormal
Day 4 hindbrain oligodendrocyte development decreased process quality, abnormal
hmgcs1vu57/vu57 + MO4-tp53 chemical treatment by environment: U0126 Day 4 hindbrain oligodendrocyte mbpa expression decreased amount, abnormal
Day 4 hindbrain oligodendrocyte plp1a expression decreased amount, abnormal
Day 4 hindbrain oligodendrocyte development decreased process quality, abnormal
Full text @ J. Neurosci.